Use of an interferon-γ release assay to diagnose latent tuberculosis infection in foreign-born patients

Chest

Volumn 133, Issue 4, 2008, Pages 869-874

  Brodie, Daniel ^a   Lederer, David J ^a   Gallardo, Jade S ^a   Trivedi, Saumil H ^a   Burzynski, Joseph N ^b   Schluger, Neil W ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

Infection; Interferon; Tuberculosis; Tuberculosis testing

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; ASSAY; BCG VACCINATION; CONTROLLED STUDY; DEVICE; FEMALE; HUMAN; INTERFERON PRODUCTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; VALIDATION STUDY;

EID: 42349104594     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1815     Document Type: Article

References (19)

1. Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54:1-81
2. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002; 346:1453-1458
3. Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192-1204
4. Brodie D, Schluger NW. The diagnosis of tuberculosis. Clin Chest Med 2005; 26:247-271, vi
5. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340-354
6. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: Royal College of Physicians, 2006
7. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999. Am J Respir Crit Care Med 2000; 161:S221-S247
8. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995; 44:19-34
9. Shams H, Weis SE, Klucar P, et al. Enzyme-linked Immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005; 172:1161-1168
10. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367:1328-1334
11. Lutong L, Bei Z. Association of prevalence of tuberculin reactions with closeness of contact among household contacts of new smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2000; 4:275-277
12. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361:1168-1173
13. Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two interferon-γ assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007; 175:618-627
14. Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-γ responses at 6 weeks following tuberculin skin testing. Eur Respir J 2007; 29:1282-1283
15. Richeldi L, Ewer K, Losi M, et al. Repeated tuberculin testing does not induce false positive ELISPOT results. Thorax 2006; 61:180
16. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006; 28:45-50
17. Dewan PK, Grinsdale J, Liska S, et al. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-γ assay. BMC Infect Dis 2006; 6:47
18. Diel R, Nienhaus A, Lange C, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28:35-44
19. Diel R, Wrighton-Smith P, Zellweger JP. Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis. Eur Respir J 2007; 30:321-332